CAR T cell therapy biotech Allogene Therapeutics sets terms for $272 million IPO

Shutterstock photo

Allogene Therapeutics, a phase 1 biotech developing off-the-shelf CAR T cell cancer therapies, announced terms for its IPO on Tuesday.

The South San Francisco, CA-based company plans to raise $272 million by offering 16 million shares at a price range of $16 to $18. At the midpoint of the proposed range, Allogene Therapeutics would command a fully diluted market value of $2.1 billion and an enterprise value of $1.4billion.

Allogene Therapeutics was founded in 2017 and plans to list on the Nasdaq under the symbol ALLO. Goldman Sachs, J.P. Morgan, Cowen and Jefferies are the joint bookrunners on the deal. It is expected to price during the week of October 8, 2018.

The article CAR T cell therapy biotech Allogene Therapeutics sets terms for $272 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs

More from Renaissance Capital


Renaissance Capital

Renaissance Capital


Research Brokers before you trade

Want to trade FX?